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Banisteriopsis caapi (B. caapi) contains harmine, harmaline, and tetrahydroharmine, has mono-
amine oxidase inhibitory activity, and has reported antiparkinsonian activity in humans when
imbibed as a tea; however, its effects are poorly documented. For this reason, motor function
was assessed in 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐treated common marmosets
following administration of B. caapi extract (28.4–113.6 mg/kg; po), harmine (0.1 and 0.3 mg/
kg; sc), and selegiline (10 mg/kg; sc), alone or with a submaximal dose of L‐3,4‐
dihydroxyphenylalanine (L‐DOPA; 4–7 mg/kg). L‐DOPA reversed motor disability, increased
locomotor activity, and induced moderate dyskinesia. B. caapi did not increase locomotor activity
or induce dyskinesia but at 56.8 and 113.6 mg/kg improved motor disability. The L‐DOPA
response was unaltered by co‐administration of B. caapi. Harmine (0.1 and 0.3 mg/kg) produced
a mild improvement in motor disability without affecting locomotor activity or dyskinesia but had
no effect on the L‐DOPA‐induced antiparkinsonian response. Selegiline (10 mg/kg) alone
improved motor function to the same extent as L‐DOPA, but with only mild dyskinesia, and did
not alter the response to L‐DOPA, although dyskinesia was reduced. The findings suggest that
B. caapi alone has a mild antiparkinsonian effect but does not enhance the L‐DOPA response
or reduce dyskinesia.
KEYWORDS
Banisteriopsis, monoamine oxidase, MPTP, Parkinson's disease, primate
1 | INTRODUCTION
Parkinson's disease (PD) is a progressive, neurodegenerative disease
that affects motor function resulting primarily from the degeneration
of dopaminergic neurons in the substantia nigra pars compacta.
Treatment is based on dopamine replacement therapy, and the
amino acid precursor of dopamine, L‐3,4‐dihydroxyphenylalanine
(L‐DOPA), is the most widely used and efficacious symptomatic
treatment; however, chronic use commonly leads to a loss of effi-
cacy and the development of unwanted involuntary movements
(dyskinesia; Ahlskog & Muenter, 2001; Fox & Lang, 2008). To extend
the duration of effect of L‐DOPA and reduce the dose required,
monoamine oxidase B (MAO‐B) inhibitors, such as selegiline and
rasagiline, are employed to inhibit the metabolism of dopamine
derived from L‐DOPA (Jenner, 2015).
Banisteriopsis caapi (B. caapi) is a liana, endemic to the Amazon,
basin known to contain a number of β‐carbolines such as harmine,
harmaline, and tetrahydroharmine that possess MAO inhibitory prop-
erties (Schwarz, Houghton, Rose, Jenner, & Lees, 2003). Extracts of
B. caapi have been shown to be effective in treating PD when used
in combination with L‐DOPA by extending its duration of action possi-
bly as a result of reduced dopamine metabolism and enhanced release
of dopamine from dopaminergic neurons (Serrano‐Duenas, Cardozo‐
Pelaez, & Sanchez‐Ramos, 2001a, 2001b). It is thought that these
effects of B. caapi are mediated through its constituent β‐carbolines
(Iurlo et al., 2001; Meneguz, Betto, & Ricciarello, 1994). Indeed,
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90 years ago, Lewin and Beringer both reported the successful use of
harmine as monotherapy in the pre‐L‐DOPA era for the treatment of
PD and although marketed in the 1920s for this purpose, it fell out
of use because of low efficacy (see Djamshidian, Bernschneider‐Reif,
Poewe, & Lees, 2016).
More recently, Meneguz et al. (1994) reported that short‐term
intravenous administration of harmine used in combination with
L‐DOPA increased its plasma concentration and raised dopamine
levels in the striatum of rats and rabbits (Iurlo et al., 2001; Meneguz
et al., 1994). This supported the idea that MAO inhibition by B. caapi
extracts underlies the antiparkinsonian activity observed, but this has
never been formally tested.
The purpose of this study was to determine the effects of B. caapi
extracts and one of its constituent β‐carbolines, harmine, on motor
dysfunction in a primate model of PD. To that end, we have used the
1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)‐treated com-
mon marmoset primed by previous chronic treatment with L‐DOPA
to exhibit dyskinesia, an established model of the motor symptoms
of PD. The treatments were evaluated both as monotherapy and in
combination with L‐DOPA and compared with the established
MAO‐B inhibitor, selegiline.
2 | MATERIALS AND METHODS
2.1 | Preparation of extract of B. caapi
Dried stem of B. caapi was obtained from Dr. Marcos Serrano‐
Duenas, Neurology Service, Carlos Andrade Marin Hospital Quito.
An extract from the dried whole stem of B. caapi was prepared as pre-
viously described (Schwarz et al., 2003), approximating to the method
of preparation of the extract used in Ecuador for the earlier clinical tri-
als in PD. The stem was ground into a powder and then refluxed
(50 g/500 ml distilled water) for 1 hr. After filtration, the remaining
plant material was refluxed (50 g/500 ml distilled water) for 1 hr as
before and filtered, and the two filtrates were combined and freeze‐
dried. The freeze‐dried aqueous extracts were then reconstituted in
methanol and analysed by high‐performance liquid chromatography
(HPLC) with diode array for levels of harmine, harmaline, and
tetrahydroharmine.
2.2 | HPLC analysis
The samples were analysed on a HP1050 HPLC system equipped
with an autosampler, a quaternary pump, and a diode‐array detec-
tor. A Zorbax SB C‐18 2.1 mm × 10 cm (particle size 3.5 micron)
column was employed. A linear gradient of mobile Phase B (aceto-
nitrile containing 0.1% trifluoroacetic acid) over mobile Phase A
(0.1% trifluoroacetic acid in water) from 0% to 50% B in 50 min
was employed at a flow rate of 0.2 ml/min, and the eluents were
monitored at wavelengths between 210 and 280 nm. Data were
collected and compared with standard curves harmine, harmaline,
tetrahydroharmine, and N,N‐dimethyltryptamine using ChemStation
software.
2.3 | Animals
All studies were performed in the same group (n = 8) of previously
MPTP‐treated common marmosets (Callithix jaccus; aged 3–10 years;
Pearce, Jackson, Smith, Jenner, & Marsden, 1995; Smith et al., 2000;
Zubair et al., 2007). Animals were housed in mixed sex or female–
female pairs under standard housing conditions (23 °C, humidity
50%). They have access to water and marmoset pellets ad libitum
and received meals of fresh fruit, cereals, and protein (e.g., egg and
chicken) twice daily. Vitamin D supplement is given once per week.
Animals were treated with MPTP between 1 and 4 years prior to
the start of the study (Smith, Jackson, Hansard, Maratos, & Jenner,
2003). Following MPTP treatment, the animals became bradykinetic
and rigid and some showed action tremor. They exhibited reduced
vocalization; however, they were able to eat, drink, and move around
the home cage unaided. All animals were responsive to L‐DOPA and
had been primed with L‐DOPA (8–12.5 mg/kg po + benserazide
(10 mg/kg po) for up to 28 days) to express dyskinesia between 1
and 4 years prior to these studies.
All experiments were performed according to the Animals
(Scientific Procedures Act) 1986 under Project Licence No 70/7146,
with local ethical approval. All animals had previously been involved
in studies involving the assessment of novel drugs for PD and received
a drug washout period of at least 4 weeks prior to the start of this
study. Drug treatments were performed according to a modified Latin
square schedule such that all animals were given all treatments on a
single occasion in a randomized manner. Experiments were performed
twice weekly with at least 72 hr between treatments to ensure
appropriate animal welfare consideration.
2.4 | Treatments
Benserazide is a DOPA‐decarboxylase inhibitor and prevents the
peripheral conversion of L‐DOPA to dopamine. Benserazide HCl
(10 mg/kg, Sigma, UK) was dissolved in 10% sucrose and then used
as the vehicle for dissolving L‐DOPA methyl ester (ME) such that
benserazide and L‐DOPA‐ME were then dosed concomitantly in the
same syringe.
L‐DOPA‐ME (Sigma, UK) was used throughout this study as it is
easily soluble and rapidly hydrolysed to the parent compound and pro-
duces the same effect as using the freebase (Brunnerguenat et al.,
1995). L‐DOPA‐ME was dissolved in 10% sucrose (containing
benserazide as above) using a salt:base ratio of 1:1.25 to provide the
freebase dose (L‐DOPA 4 or 7 mg/kg). All doses were corrected for
freebase and referred to as L‐DOPA.
L‐DOPA was administered at a submaximal dose determined from
dose ranging studies (data not shown) and performed in the animals
immediately prior to the present studies. The dose volume was 2 ml/
kg administered by oral gavage (po).
Domperidone HCl (2 mg/kg, Sigma, UK) was prepared as a suspen-
sion in 10% sucrose and administered orally at a dose volume of 2 ml/
kg, 1 hr prior to treatment to prevent vomiting.
B. caapi was analysed for content of harmine, harmaline, and
tetrahydroharmine, which are known to be the three main chemicals
in this plant. The stem extracts contained 35.2 mg/g extract of
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harmine, 17.6 mg/g extract of tetrahydroharmine, and no harmaline
(Figure 1a,b). B. caapi extract (28.4, 56.8, or 113.6 mg/kg) was dis-
solved in 20% Kleptose HPB (hydroxypropyl‐beta‐cyclodextrin‐
HPBCD, Roquette pharma, France) and administered by oral gavage
(po) at a dose volume of 2 ml/kg.
Harmine HCL (Santa Cruz Biotechnology, Germany) was dissolved
in 0.9% sterile saline (Baxter Healthcare Ltd., UK) using a salt: base ratio
of 1:1.17 to provide the freebase dose (Harmine 0.1 and0.3mg/kg). The
dose volume was 1 ml/kg administered by subcutaneous injection (sc).
Selegiline HCl (Sigma, UK) was dissolved in 0.9% sterile saline
(Baxter Healthcare Ltd., UK) using a salt base ratio of 1:1.195 to
provide the freebase dose of selegiline (10 mg/kg). The dose volume
was 1 ml/kg administered by subcutaneous injection (sc).
2.5 | Administration of B. caapi extract
Animals were treated with B. caapi extract (28.4, 56.8, or
113.6 mg/kg po) or vehicle (20% Kleptose po) in combination with
a submaximal dose of L‐DOPA (7 mg/kg po) or vehicle (10%
sucrose po).
Initially a dose of B. caapi extract (8.5 mg/2 ml po), equivalent to
harmine (0.3 mg/kg), was given to all animals in their home cage. No
changes in activity or disability were noted (data not shown). Impor-
tantly, the animals drank the concentrated tea with no adverse effect.
Therefore, the lowest dose of B. caapi extract chosen (28.4 mg/kg) was
equivalent to drinking 2.36 ml/kg of the original tea and contained the
equivalent of 1 mg/2 ml harmine.
On the day of the study, B. caapi extract or vehicle was
administered immediately prior to L‐DOPA (7 mg/kg, po) or vehicle
at t = 0 hr. All drug combinations were administered in a random-
ized manner according to a modified Latin square such that all
animals received all treatments with at least 2 days between each
treatment.
2.6 | Administration of harmine
Animals were treated with harmine (0.1 and 0.3 mg/kg, sc) or vehi-
cle (0.9% saline sc) in combination with a submaximal dose of L‐
DOPA (4 mg/kg, po) or vehicle (10% sucrose po). Harmine or vehi-
cle was administered immediately prior to administration of L‐DOPA
(4 mg/kg, po) or vehicle. Drugs were administered in a randomized
manner according to a modified Latin square such that all animals
received all drug combinations with at least 2 days between each
treatment.
2.7 | Administration of selegiline
The effect of selegiline (10 mg/kg, sc) on basal and L‐DOPA (4 mg/kg,
po)‐induced motor activity was investigated as positive control in a
separate experiment. Animals were treated with either selegiline
(10 mg/kg sc) plus vehicle (10% sucrose po) or selegiline (10 mg/kg
sc) plus a submaximal dose of L‐DOPA (4 mg/kg, po). Selegiline was
administered 60 min prior to L‐DOPA (4 mg/kg, po) or vehicle at
t = −60 min. Treatments were administered in a crossover design with
1 week between each treatment to allow washout of drug due to the
long half‐life of selegiline.
2.8 | Behavioural assessment
On test days, the animals were removed from their home cages before
presentation of breakfast and were placed individually into automated
test units (Smith et al., 2002). They were allowed a 60‐min acclimatiza-
tion period prior to treatment during which basal locomotor activity,
motor disability, and dyskinesia were assessed before (baseline) and
for up to a maximum of 6 hr as described below.
2.9 | Locomotor activity
Each automated test unit (50 × 60 × 90 cm) was fitted with a clear
Perspex door to facilitate observation and equipped with eight
horizontally orientated photoelectric emitters/detectors (light beams),
arranged to permit optimal assessment of activity. Interruption of a
light beam was automatically recorded as a single locomotor count
accumulated in 10‐ and 30‐min intervals for 5 hr following drug
treatment.
FIGURE 1 High‐performance liquid chromatography (HPLC) traces of
tetrahydroharmine, harmine, and harmaline in the reconstituted
freeze‐dried aqueous extract of Banisteriopsis caapi. The extract from
the dried whole stem of B. caapi was analysed by HPLC with diode
array at wavelengths between 210 and 280 nm for levels of
(a) tetrahydroharmine, (b) harmaline, and (c) harmine. HPLC traces from
(a) standard containing 0.3 mg/ml of all alkaloids and (b) original
B. caapi extract [Colour figure can be viewed at wileyonlinelibrary.com]
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2.10 | Motor disability
Motor disability was assessed simultaneously with locomotor activity
through a one‐way mirror by experienced observers blinded to treat-
ment. Basal disability was assessed before and once every 30 min after
drug treatment for 5 hr using an established motor disability rating
scale; alertness (normal = 0, reduced = 1, sleepy = 2); checking
(present = 0, reduced = 1, absent = 2); posture (normal = 0, abnormal
trunk +1, abnormal tail +1, abnormal limbs +1, flexed = 4); balance
(normal = 0, impaired = 1, unstable = 2, spontaneous falls = 3); reaction
to stimuli (normal = 0, reduced = 1, slow = 2, absent = 3); vocalization
(normal = 0, reduced = 1, absent = 2); motility (normal = 0, bradykine-
sia = 1, akinesia = 2). These values were summed, a maximum score of
18 indicating severe motor disability, a minimum score of 0 indicating
maximum reversal of motor disability.
2.11 | Dyskinesia
Dyskinesia was assessed simultaneously with motor disability by expe-
rienced observers blinded to treatment. Basal dyskinesia was assessed
before and once every 30 min after drug treatment for 5 hr using an
established dyskinesia rating scale; 0 = absent; 1 = mild, fleeting, and
rare dyskinetic postures and movements; 2 = moderate: more prominent
abnormal movements, but not significantly affecting normal behaviour;
3 = marked, frequent and at times continuous dyskinesia affecting the
normal pattern of activity; 4 = severe, virtually continuous dyskinetic
activity, disabling to the animal and replacing normal behaviour.
2.12 | Data and statistical analysis
Data are presented as median in time course and area under curve
(AUC) (calculated over 5 hr using the trapezoid method from the time
course curves, Graphpad Prism®).
Motor disability and dyskinesia scores were transformed using the
formula Y = √(Y) prior to statistical analysis. Changes in the AUC for
locomotor activity, reversal of motor disability, and dyskinesia expres-
sion were then analysed using a repeated measures one‐way analysis
of variance (ANOVA) and Newman–Keuls test. Significance was set
at p < .05 for all analyses and performed using GraphPad Prism Version
5.00 for Windows (GraphPad Software, San Diego California USA,
www.graphpad.com).
3 | RESULTS
3.1 | The effect of B. caapi alone and combined with
L‐DOPA (7 mg/kg, po) on locomotor activity, motor
disability, and dyskinesia
Neither vehicle treatments (Kleptose or sucrose) had any effect on
motor disability, locomotor activity and did not induce dyskinesia
(Figure 2a–f); however, the submaximal dose of L‐DOPA (7 mg/kg,
po) produced a significant reversal of motor disability, an increase in
locomotor activity and induced moderate to severe dyskinesia. B. caapi
improved overall motor disability scores with a U‐shaped dose
response curve, with a maximum, but moderate reversal of motor
disability following 56.8 mg/kg. This reversal was significantly different
to vehicle following both 56.8 and 113.6 mg/kg B. caapi alone (Figure 2
b). No one aspect of motor disability was specifically affected by
B. caapi treatment. By contrast, at all doses investigated (28.4 to
113.6 mg/kg), B. caapi alone had no effect on locomotor activity and
did not induce dyskinesia (Figures 2c–f). When given in combination
with a submaximal dose of L‐DOPA (7 mg/kg, po), B. caapi produced
no significant alteration to the L‐DOPA (7 mg/kg, po) response,
although L‐DOPA (7 mg/kg, po)‐induced locomotor activity was some-
what reduced with increasing dose of B. caapi, but this was not statis-
tically significant (Figure 2d). The lowest dose of B. caapi (28.4 mg/kg)
caused a slight reduction in L‐DOPA (7 mg/kg, po)‐induced total dyski-
nesia score; however, this reduction was not statistically different
when compared with L‐DOPA (7 mg/kg, po) alone (Figure 2f).
3.2 | The effect of treatment with harmine alone and
in combination with L‐DOPA (4 mg/kg, po) on
locomotor activity, motor disability, and dyskinesia
As expected, the submaximal dose of L‐DOPA (4 mg/kg, po) produced
a significant reversal of motor disability, an increase in locomotor activ-
ity, and expression of mild to severe dyskinesia (Figure 3a–f). The
higher dose of harmine (0.3 mg/kg sc) alone produced a small reversal
of motor disability that lasted for about 2 hr with total scores signifi-
cantly improved compared with vehicle (Figure 3b). By contrast,
harmine had no effect on locomotor activity at any dose given alone
(Figure 3c,d). Although three animals showed a fleeting display of
abnormal movements, the dyskinesia scores were also not significantly
different to control (Figures 3e,f).
L‐DOPA (4 mg/kg, po)‐induced reversal of motor disability or
increase in locomotor activity was not altered by any dose of harmine
(0.1 and 0.3 mg/kg sc) (Figures 3a–d).
The severity of L‐DOPA (4 mg/kg, po)‐induced peak dose
dyskinesia seen 1 hr after dosing tended to be increased by harmine
(0.1 and 0.3 mg/kg; Figure 3e,f), although the scores were not signifi-
cantly different to L‐DOPA (4 mg/kg, po) alone. No one individual com-
ponent of themotor disability scoreswas specifically altered by harmine
except in two animals where existing action tremor was worsened.
3.3 | The effect of treatment with selegiline alone
and in combination with L‐DOPA (4 mg/kg, po) on
locomotor activity, motor disability, and dyskinesia
Selegiline (10 mg/kg, sc) alone produced a similar reversal of motor dis-
ability and increase in locomotor activity as the submaximal dose of
L‐DOPA (4 mg/kg, po), although with a reduced peak effect. Motor
disability was significantly improved compared with vehicle
(Figures 4a–d). Overall motor disability reversal and locomotor activity
induced by L‐DOPA (4 mg/kg, po) was not altered by selegiline
(Figures 4b,d); however, the duration of effect was increased with
improved motor disability scores (score < 8) up to 210 min compared
with 150 min with L‐DOPA alone. Interestingly, when given alone,
selegiline produced fleeting dyskinesia in some animals (scores 1–2),
which did not persist but significantly reduced the L‐DOPA (4 mg/kg,
po)‐induced dyskinesia (Figure 4f).
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4 | DISCUSSION
Previous studies suggest that extracts of B. caapi may possess
antiparkinsonian activity based on limited clinical experience in
humans (Sanchez‐Ramos, 1991; Serrano‐Duenas et al., 2001a,
2001b). This activity may relate to the monoamine oxidase inhibitory
actions of the β‐carboline content of these extracts and to the sub-
sequent effects that their actions have on dopamine metabolism and
release in the striatum (Gerardy, 1994; Meneguz et al., 1994). How-
ever, alternative mechanisms have been proposed. For example,
FIGURE 2 The effect of Banisteriopsis caapi extract (28.4, 56.8, and 113.6 mg/kg), L‐3,4‐dihydroxyphenylalanine (L‐DOPA) (7 mg/kg), and vehicle
on locomotor activity, reversal of motor disability, and dyskinesia. Treatment was administered at T = 0, and data are presented as the median
values per 30 min for time course data and the median (n = 8) and individual values for total (area under curve [AUC]) data. (a) The time course of
effect on motor disability following treatment with B. caapi alone and in combination with L‐DOPA (7 mg/kg, po). (b) The total reversal of motor
disability (AUC) following treatment with B. caapi alone and in combination with L‐DOPA (7 mg/kg, po). * indicates values that are significantly
different (p < .0001, F value = 15.99, degrees of freedom = 7 one‐way analysis of variance (ANOVA) for repeated measures and p < .05 Newman–
Keuls multiple comparison test). (c) The time course of effect on locomotor activity following treatment with B. caapi alone and in combination with
L‐DOPA (7 mg/kg, po). (d) Total locomotor activity (AUC) following treatment with B. caapi alone and in combination with L‐DOPA (7 mg/kg, po). *
indicates values that are significantly different (p < .0001, F value = 15.52, degrees of freedom = 7 one‐way ANOVA for repeated measures and
p < .05 Newman–Keuls multiple comparison test). (e) The time course of effect on dyskinesia following treatment with B. caapi and in combination
with L‐DOPA (7 mg/kg, po). (f) Total dyskinesia (AUC) following treatment with B. caapi alone and in combination with L‐DOPA (7 mg/kg, po). *
indicates values that are significantly different (p < .0001, F value = 23.55, degrees of freedom = 7, one‐way ANOVA for repeated measures and
p < .05 Newman–Keuls multiple comparison test)
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Serrano‐Duenas et al. (2001a, 2001b) suggested that the beneficial
effects of B. caapi were the result of N‐Methyl‐D‐aspartate‐receptor
antagonist effect of the constituent β‐carbolines. In addition, there is
evidence that harmine, a component of B. caapi, increases striatal
dopamine release (Iurlo et al., 2001) and can enhance L‐DOPA‐
induced stereotypy in normal mice (Pimpinella & Palmery, 1995),
However, there is little direct pharmacological evidence for the
potential of B. caapi extracts to exert an effect on motor function
when administered alone, or in combination with L‐DOPA, in rela-
tion to their potential antiparkinsonian activity in humans. To this
FIGURE 3 The effect of treatment with harmine (0.1 and 0.3 mg/kg sc), L‐3,4‐dihydroxyphenylalanine (L‐DOPA) (4 mg/kg po), and vehicle on
locomotor activity, reversal of motor disability, and dyskinesia. Treatment was administered at T = 0, and data are presented as the median
values per 30 min for time course data and the median (n = 8) and individual values for total (area under curve [AUC]) data. (a) The time course of
effect on motor disability following treatment with harmine alone and in combination with L‐DOPA (4 mg/kg, po). (b) The total reversal of motor
disability (AUC) following treatment with harmine alone and in combination with L‐DOPA (4 mg/kg, po). * indicates values that are significantly
different (p < .0001, F value = 44.34, degrees of freedom = 5 one‐way analysis of variance (ANOVA) for repeated measures and p < .05 Newman–
Keuls multiple comparison test). (c) The time course of effect on locomotor activity following treatment with harmine alone and in combination with
L‐DOPA (4 mg/kg, po). (d) Total locomotor activity (AUC) following treatment with harmine alone and in combination with L‐DOPA (4 mg/kg, po). *
indicates values that are significantly different (p < .0001, F value = 10.81, degrees of freedom = 5 one‐way ANOVA for repeated measures and
p < .05 Newman–Keuls multiple comparison test). (e) The time course of effect on dyskinesia following treatment with harmine alone and in
combination with L‐DOPA (4 mg/kg, po). (f) Total dyskinesia (AUC) following treatment with harmine alone and in combination with L‐DOPA
(4 mg/kg, po). * indicates values that are significantly different (p < .0001, F value = 20.38, degrees of freedom = 5, one‐way ANOVA for repeated
measures and p < .05 Newman–Keuls multiple comparison test)
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end, we have carried out the first ever examination of extracts of
B. caapi in the most predictive primate model of drug effect in PD
to assess the potential for symptomatic activity. We examined both
the effects of B. caapi alone and its effects when combined with a
submaximal dose of L‐DOPA (4 and 7 mg/kg, po). We compared
the effect of the extracts with that of one of the constituent
β‐carbolines, harmine and with the clinically relevant MAO‐B
inhibitor, selegiline.
FIGURE 4 The effect of treatment with selegiline (10 mg/kg sc), L‐3,4‐dihydroxyphenylalanine (L‐DOPA) (4 mg/kg po), and vehicle on locomotor
activity, reversal of motor disability, and dyskinesia. Treatment was administered at T = 0, and data are presented as the median values per 30 min
for time course data and the median (n = 8) and individual values for total (area under curve [AUC]) data. (a) The time course of effect on motor
disability following treatment with selegiline alone and in combination with L‐DOPA (4 mg/kg, po). (b) The total reversal of motor disability (AUC)
following treatment with selegiline alone and in combination with L‐DOPA (4 mg/kg, po). * indicates values that are significantly different
(p < .0001, F value = 12.6, degrees of freedom = 3 one‐way analysis of variance (ANOVA) for repeated measures and p < .05 Newman–Keuls
multiple comparison test). (c) The time course of effect on locomotor activity following treatment with selegiline alone and in combination with L‐
DOPA (4 mg/kg, po). (d) Total locomotor activity (AUC) following treatment with selegiline alone and in combination with L‐DOPA (4 mg/kg, po). *
indicates values that are significantly different (p = .0242, F value = 3.856, degrees of freedom = 3 one‐way ANOVA for repeated measures and
p < .05 Newman–Keuls multiple comparison test). (e) The time course of effect on dyskinesia following treatment with selegiline alone and in
combination with L‐DOPA (4 mg/kg, po). (f) Total dyskinesia (AUC) following treatment with selegiline alone and in combination with L‐DOPA
(4 mg/kg, po). * indicates values that are significantly different (p < .0001, F value = 11.41, degrees of freedom = 3, one‐way ANOVA for repeated
measures and p < .05 Newman–Keuls multiple comparison test)
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The MPTP‐treated primate is highly responsive to L‐DOPA treat-
ment, and as expected from previous studies, administration of a sub-
maximal dose (4–7 mg/kg) of the drug reversed the bradykinesia
shown by these animals and normalized motor function as indicated
by the reversal of motor disability scores. The drug also induced invol-
untary movements in the animals as they had been primed by prior
L‐DOPA exposure to exhibit dyskinesia (Pearce et al., 1995). In a sim-
ilar manner, the higher doses of B. caapi administered alone also pro-
duced some reversal of motor disability although not to the same
extent as L‐DOPA (7 mg/kg, po). In contrast to L‐DOPA (7 mg/kg,
po), there was no increase in locomotor activity and no induction of
dyskinesia. This is of interest as increased locomotor activity parallels
more closely the induction of dyskinesia than an improvement in
motor function related to antiparkinsonian efficacy (Kuoppamaki
et al., 2007). This selective effect on motor disability suggests that it
may exert an antiparkinsonian action in humans in the absence of
the expression of established dyskinesia and would distinguish B. caapi
extract from the effects of currently used dopaminergic medications.
However, when combined with a submaximal dose of L‐DOPA
(7 mg/kg, po), the effects of the B. caapi extract were not additive as
no improvement in motor disability was seen over and above that pro-
duced by L‐DOPA (7 mg/kg, po) alone. Similarly, there was no change
in the increased locomotor activity or dyskinesia induction produced
by L‐DOPA (7 mg/kg, po). These results suggest that the mild
antiparkinsonian effect of B. caapi may be relevant to early monother-
apy in PD but not to the later stages of the disease where adjunct ther-
apy with L‐DOPA would be employed. Importantly, the doses of the
extract of B. caapi were clinically relevant as the lowest dose was
equivalent to drinking approximately 150 ml of the original tea in
humans. This is consistent with a study in patients with PD where a
significant improvement in motor function was reported following a
single dose (200 ml) of B. caapi tea (Sanchez‐Ramos, 1991;
Serrano‐Duenas et al., 2001a, 2001b).
The question then arises as to whether the modest effects seen
with B. caapi extracts reflect the monoamine oxidase inhibitory actions
of the constituent β‐carbolines. The tea was analysed for content of
harmine, harmaline, and tetrahydroharmine and found that harmine
and tetrahydroharmine, but not harmaline, was present in the tea. This
was surprising as previously it has been reported that harmaline is pres-
ent in the vine; however, levels of harmaline have previously been
reported as low (10% of that of harmine; Callaway, Brito, & Neves,
2005).The reason for this difference is not clear but may be due to dif-
ferences in the extraction processes involved in the analysis. Indeed,
in this study, we prepared the B. caapi as a tea as it was prepared in
water as for earlier clinical trials (Serrano‐Duenas et al., 2001a,
2001b), which was freeze‐dried and then reconstituted with methanol,
whereas in the analysis by Callaway et al. (2005), the samples were
solely extracted by methanol.
Administration of the major β‐carboline component of B. caapi,
harmine, at a dose equivalent to that found in the tea extract, produced
a modest but significant reversal of motor disability without increased
locomotor activity or dyskinesia. This would support a MAOI‐based
effect of B. caapi extracts but cannot exclude the possibility of other
pharmacological effect. Harmine has been shown to increase striatal
dopamine efflux both in vitro (Schwarz et al., 2003) and in vivo in rats
at equivalent doses (Iurlo et al., 2001). As harmine is a selective inhibitor
of MAO‐A, and this isoform does not contribute to the metabolism of
dopamine in the striatum, it is more likely that this direct effect on DA
release explains the reversal of motor disability.
Interestingly, the modest improvement in motor disability was not
obvious when harmine was combined with a submaximal dose of
L‐DOPA (4 mg/kg, po). This is in line with the reported effect of com-
bined treatment with a MAOBI and L‐DOPA in PD patients but contra-
dicts findings in 6‐OHDA lesioned rats where selegiline potentiated
the effects of L‐DOPA (Brannan & Yahr, 1995; Macinnes & Duty,
2004; Prat, Perez, Rubi, Casas, & Unzeta, 2000; Skuza, Rogoz, Quack,
& Danysz, 1994). However, it would depend on the extent to which
the doses of harmine used blocked MAO activity in the brain and the
relative selectivity for MAO‐A and MAO‐B, as it is the latter that is
believed to control synaptic dopamine concentrations in the dener-
vated striatum in PD, and prior studies have indicated that harmine
has little inhibitory effect on MAO‐B (Schwarz et al., 2003).
To assess what changes in motor function would be expected if
inhibition of MAO‐B activity contributed to the effects of B. caapi
extracts or harmine, we compared the changes observed to those pro-
duced by the selective MAO‐B inhibitor, selegiline. In PD, selegiline is
used both as monotherapy for its mild symptomatic effects and in later
disease as an adjunct to L‐DOPA therapy. In the MPTP‐treated pri-
mate, administration of selegiline reversed motor disability and
increased locomotor activity with little or no expression of dyskinesia.
These effects were more marked than seen with either B. caapi
extracts or harmine and suggest that the actions of B. caapi and
harmine are not wholly dependent on MAO‐B inhibition or that they
have a weak inhibitory effect at the doses used. This is in line with
the evidence suggesting that both harmine and extracts of B. caapi
have selective inhibitory activity at MAO‐A, with little or no effect
on MAO‐B but that both have modest dopamine releasing properties
(Schwarz et al., 2003). As for B. caapi and harmine, selegiline adminis-
tration did not potentiate the effects of a submaximal dose of L‐DOPA
(4 mg/kg, po) on motor disability and locomotor activity, and although
it reduced the peak effects of L‐DOPA (4 mg/kg, po), it tended to
increase the duration of response, while reducing the expression of
L‐DOPA‐induced dyskinesia. This was unexpected as it does not
reflect the clinically accepted effect of selegiline in enhancing
dopamine's effect in humans. A MAO‐B inhibitor might be expected
to potentiate the effects of dopamine formed from L‐DOPA at the
striatal level (Macinnes & Duty, 2004; Prat et al., 2000; Skuza et al.,
1994). Indeed, although selegiline did not alter the overall score for
motor disability, the duration of activity, as measured by a score less
than 8, was increased by about 1 hr, reflecting the extension of
L‐DOPA's response and reduced end of dose deterioration reported
clinically (Fabbrini, Abbruzzese, Marconi, & Zappia, 2012; Lyytinen,
Kaakkola, Gordin, Kultalahti, & Teravainen, 2000). To our surprise,
we could find no prior investigation of the symptomatic effects of
selegiline in MPTP‐treated primates, with the exception of one review
that suggests that administration of selegiline increased the
antiparkinsonian effects of levodopa and decreased dopamine
metabolites (Nomoto, 1995).
Although there is some suggestion that some β‐carbolines can be
neurotoxic (Haghdoost‐Yazdi, Hosseini, Faraji, Nahid, & Jahanihashemi,
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2010;Ostergren, Fredriksson, & Brittebo, 2006; Ostergren, Lindquist, &
Brittebo, 2007), evidence suggests that harmine is, if anything, neuro-
protective with antiinflammatory and antiapoptotic activity (Liu et al.,
2017; Zhong, Tao, & Yang, 2015) that could be beneficial in the chronic
treatment of PD. In addition, these results in theMPTP‐treated primate
provide support for the reports of the benefits of B. caapi and harmine
monotherapy as a mild symptomatic treatment for early PD (Sanchez‐
Ramos, 1991; Serrano‐Duenas et al., 2001a, 2001b), as there was little
or no evidence to show that therewas any additive or synergistic action
in conjunction with L‐DOPA that is indicated for mid to late stages of
the disease. The effects seen may be due at least in part to the MAO
inhibitory actions of some of the constituents of B. caapi extract
although a direct action on dopamine release cannot be excluded.
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